Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;59(10):6605-7.
doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Romney M Humphries  1 , Shangxin Yang  2 , Peera Hemarajata  2 , Kevin W Ward  2 , Janet A Hindler  1 , Shelley A Miller  2 , Aric Gregson  3
Affiliations

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Romney M Humphries et al. Antimicrob Agents Chemother. 2015 Oct.

Abstract

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.

PubMed Disclaimer

References

    1. Bush K. 2013. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci 1277:84–90. doi: 10.1111/nyas.12023. - DOI - PubMed
    1. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother 58:833–838. doi: 10.1128/AAC.01896-13. - DOI - PMC - PubMed
    1. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. 2010. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother 54:890–897. doi: 10.1128/AAC.00693-09. - DOI - PMC - PubMed
    1. Pollett S, Miller S, Hindler J, Uslan D, Carvalho M, Humphries RM. 2014. Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013. J Clin Microbiol 52:4003–4009. doi: 10.1128/JCM.01397-14. - DOI - PMC - PubMed
    1. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother 59:3509–3517. doi: 10.1128/AAC.00163-15. - DOI - PMC - PubMed

MeSH terms